Apotex biosimilar of Amgen's Neulasta under FDA review
This article was originally published in Scrip
Executive Summary
The FDA has accepted another biosimilar application, this time Apotex's version of pegfilgrastim, which is referenced from Amgen's innovative drug Neulasta, which raked in about $3.6bn in sales in 2013.
You may also be interested in...
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
The FDA's rejection of Sandoz Inc.'s version of Amgen's Neulasta (pegfilgrastim) has revealed the hard truth that chasing the biosimilar market may be a riskier and more costly endeavor than companies anticipated.
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
The FDA's rejection of Sandoz Inc.'s version of Amgen's Neulasta (pegfilgrastim) has revealed the hard truth that chasing the biosimilar market may be a riskier and more costly endeavor than companies anticipated.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.